Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFlorida Blue Responsible Steps Prior Auth Coverage…
    Ask Trek AI about this page
    CurrentFlorida BluePolicy N/A

    Responsible Steps Program Information and Authorization Forms

    Customize your policy alerts

    Sign up for all Florida Blue policy alerts

    Know when Florida Blue releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Provides lists of target drugs by therapeutic category and the prerequisite prior-use (step) medications required for prior authorization within the Responsible Steps Program; links to authorization forms are referenced. Covers many classes (antidepressants, atypical antipsychotics, gabapentin-related products, SGLT2 inhibitors, phosphate binders, topical corticosteroids, atopic dermatitis agents, etc.) and specifies required prior use (generic agents, number required, or condition-specific alternatives).

    Policy Summary
    PayerFlorida Blue
    PolicyResponsible Steps Program Information and Authorization Forms
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date
    Last ReviewApr 1, 2026
    Next Review Date
    Key ActionProviders must use the authorization form that matches the therapeutic category of the target drug and document prior use of the specific generic prerequisite drugs as listed for the target drug and indication.
    SourceLink
    POLICY UPDATE CHANGES

    No material changes to policy (has_material_change=false).

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Multiple
    Therapeutic categories covered
    ManyTarget drugs listed
    SpecificPrerequisite prior-use requirements

    Coverage Summary

    The Responsible Steps Program requires documented prior-use (step) therapies before target drugs will be authorized; it maps many target drugs across therapeutic categories to specified prerequisite generic alternatives or alternative agents and references category-specific authorization forms. Coverage stance: covered with criteria when the listed prerequisite prior-use requirements are met.

    Surface metadata
    last_review2026-04-01
    statusCURRENT
    subjectResponsible Steps Program prior authorization prerequisites for specialty drugs
    payerResponsible Steps Program
    policy_titleResponsible Steps Program Information

    General Program Rules

    Antidepressants — Initial Criteria

    Atypical Antipsychotics — Initial Criteria

    Atypical Antipsychotics

    Target drugs and prerequisite requirement:

    Atypical antipsychotics prerequisites: Previous use of two or more generic versions of aripiprazole, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone. *Lybalvi requires only one generic.

    Target examples: Abilify, Abilify MyCite, Fanapt, Fanapt titration pack, Geodon, Invega, Lybalvi, Opipza, Quetiapine 150 mg IR tablet, Risperdal, Risperidone 0.25 mg ODT, Saphris, Secuado, Seroquel, Seroquel XR, Symbyax, Versacloz, Zyprexa, Zyprexa Zydis.

    Gabapentin-Related Products & Indications

    Gabapentin-related products and indications

    Target drugs and prerequisites vary by indication/target product:

    Gabapentin once-daily and related targets: Previous use of generic immediate-release gabapentin is required for many mappings; specific prerequisites depend on the target (see labeled branches).

    Target examples: Gabapentin once-daily (generic Gralise), Gralise, Horizant

    Insomnia Agents: Previous use of a generic non-benzodiazepine hypnotic such as eszopiclone, zaleplon, or zolpidem IR or ER tablet is required for listed insomnia agents.

    Target examples: Ambien, Ambien CR, Belsomra, Dayvigo, Edluar, Intermezzo, Lunesta, Quviviq, Rozerem, Silenor, Zolpidem tartrate sublingual tablet, Zolpidem tartrate 7.5 mg capsule.

    Lyrica and pregabalin ER equivalents: Previous use of generic immediate‑release gabapentin = previous use of generic pregabalin IR; for Lyrica CR prerequisite requires previous use of BOTH generic pregabalin IR AND pregabalin ER.

    SGLT2 Inhibitors — Prerequisites

    SGLT2 Inhibitors and related prerequisites

    Links target SGLT2 drugs to prerequisite documentation of prior therapy:

    SGLT2 targets mapping to insulin/metformin prerequisites: For listed SGLT2 targets (bexagliflozin, Brenzavvy, Glyxambi, Invokamet, Invokamet XR, Invokana, Qtern, Segluromet, Steglatro, Steglujan, Synjardy, Synjardy XR, Trijardy XR, Xigduo XR) requirement = current use of insulin or insulin combination product OR current or previous use of brand or generic versions of insulin or metformin (alone or in combination).

    Also links Dexcom and FreeStyle systems to these SGLT2 targets.

    Additional SGLT2 targets with broader concomitant therapy requirements: For dapagliflozin, Farxiga, Inpefa, Jardiance requirement = current use of insulin or insulin combination product OR current or previous use of brand or generic versions of insulin, metformin, ACE inhibitor, ARB, ANRI (e.g., Entresto), If channel inhibitor (e.g., Corlanor), aldosterone antagonist, beta blocker, isosorbide dinitrate, or hydralazine (alone or part of a combination product).

    Target examples: Dapagliflozin, Farxiga, Inpefa, Jardiance; also associated with Dexcom/FreeStyle system listings.

    Phosphate Binders — Prerequisites

    Phosphate Binders

    Prerequisite prior use rules for phosphate binders and substitutes:

    Non-targeted phosphate binder plus Auryxia required for some targets: Previous use of BOTH a non-targeted generic phosphate binder (such as calcium acetate, calcium carbonate, calcium carbonate‑magnesium acetate, lanthanum carbonate, sevelamer HCl, or sevelamer carbonate) AND Auryxia is required for targets: Fosrenol, Renvela, Velphoro.
    Auryxia prerequisites (alternative options): For Auryxia (and Ferric Citrate 210 mg tablet authorized generic of Auryxia) previous use of EITHER a generic iron supplement OR a non‑targeted generic calcium‑containing phosphate binder is required; some mappings also list combination of generic iron supplement OR non‑targeted binder AND Auryxia.

    Target examples: Auryxia, Ferric Citrate 210 mg tablet

    Miscellaneous Mappings

    Miscellaneous

    Other mappings and prerequisites:

    Kerendia prerequisite: Previous use of any product containing an SGLT2 inhibitor (examples: Farxiga, Jardiance, Synjardy, Synjardy XR, Glyxambi, Trijardy XR) is required for Kerendia.

    Target example: Kerendia

    Topical Drugs, Atopic Dermatitis, and Topical Corticosteroids

    Topical Drugs / Atopic Dermatitis / Topical Corticosteroids

    Defines target topical agents and prerequisite topical steroid use by potency groups:

    Atopic dermatitis agents prerequisite: Previous use of a topical corticosteroid or topical corticosteroid combination product (including but not limited to betamethasone, clobetasol, desonide, desoximetasone, fluocinolone, fluocinonide, hydrocortisone, triamcinolone, diflorasone, or mometasone) is required prior to coverage of atopic dermatitis agents.

    Target examples: Elidel cream, Eucrisa ointment, pimecrolimus cream, tacrolimus ointment

    Topical corticosteroids potency groups and two-or-more generic requirement: For many potency groups the policy requires previous use of two or more generic versions of listed agents. Example groups from Super‑High (Group 1) through Lowest (Group 7) list specific agents and note the 'previous use of two or more generic versions' requirement where specified (e.g., Group 1 Super‑High: betamethasone dipropionate (augmented) 0.05% gel, Diprolene 0.05% ointment; Group 6 Low Potency includes fluocinolone acetonide 0.01% cream with specified NDCs).

    See groups listing for specific agents and two‑or‑more generic requirement.

    Provider Actions & Authorization Requirements

    Prior Authorization

    Submit authorization form by therapeutic category

    Providers must submit the prior authorization request using the authorization form that matches the therapeutic category of the target drug. The program references a page listing authorization forms — select the document matching the therapeutic category of the drug (for example, select the Antidepressants document for Cymbalta).

    Documentation Required

    Document prior use of prerequisite drugs

    Document the member’s prior use of the specific prerequisite generic drug(s) or combinations listed for the target drug and indication. Where the policy specifies a required count (for example, “two or more generic versions” for many topical corticosteroid potency groups or antidepressant requirements for some targets), include documentation of the number and identity of prior generics used. Also document indication‑specific alternatives when listed (for example neuropathic pain, fibromyalgia, or chronic musculoskeletal pain alternatives for Cymbalta).

    Applicable Codes

    No procedure/CPT/HCPCS codes listedmixed
    No codes listed
    NDC example referenced in topical listNDC
    00713-0223-15Fluocinolone acetonide 0.01% cream (NDC example in policy)
    00713-0223-60Fluocinolone acetonide 0.01% cream (NDC example in policy)

    Definitions

    Target Drug: The drug included in the Responsible Steps Program for which prior authorization and prerequisite use are defined.

    Prerequisite Drugs: Specified generic drug(s) or prior therapies that must have been used before authorization of the target drug.

    The Responsible Steps Program defines prerequisite (step) therapies required for prior authorization of target drugs and maps each target drug to specific prior-use requirements by therapeutic category; providers must submit the authorization form matching the therapeutic category and document prior use of the specified prerequisite drugs as listed for each target drug and indication.

    Clinical Evidence & Rationale

    This brief summarizes how the policy maps step-therapy prerequisites to individual target drugs across therapeutic categories. Specific clinical evidence citations or trial metric details are not included in this brief.

    Revision History

    2026-04-01reviewLatest

    Most recent policy review of the Responsible Steps Program (Current 4/1/26).

    Policy Summary
    PayerFlorida Blue
    PolicyResponsible Steps Program Information and Authorization Forms
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date
    Last ReviewApr 1, 2026
    Next Review Date
    Key ActionProviders must use the authorization form that matches the therapeutic category of the target drug and document prior use of the specific generic prerequisite drugs as listed for the target drug and indication.
    SourceLink
    On This Page
    Coverage SummaryGeneral Program RulesAntidepressants — Initial CriteriaAtypical Antipsychotics — Initial CriteriaGabapentin-Related Products & IndicationsSGLT2 Inhibitors — PrerequisitesPhosphate Binders — PrerequisitesMiscellaneous MappingsTopical Drugs, Atopic Dermatitis, and Topical CorticosteroidsProvider Actions & Authorization RequirementsApplicable CodesDefinitionsClinical Evidence & RationaleRevision History

    Target examples: Lyrica, pregabalin ER, Lyrica CR

    Savella: Previous use of a generic version of amitriptyline, cyclobenzaprine, desipramine, duloxetine, gabapentin IR, imipramine, nortriptyline, pregabalin IR, tramadol, or venlafaxine is required for Savella.

    Target example: Savella

    Triptans and related: Previous use of ANY of the following generic triptans: eletriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, or zolmitriptan ODT is required for listed triptans; for Symbravo previous use of BOTH generic rizatriptan+meloxicam combination AND meloxicam in combination with ANY of eletriptan, naratriptan, sumatriptan, zolmitriptan or zolmitriptan ODT is required.

    Target examples: almotriptan, Frova, Imitrex, Maxalt, Onzetra Xsail, Relpax, Treximet, Zembrace Symtouch, Zolmitriptan spray, Zomig nasal spray, Symbravo